Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC statins

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription sale of 10 mg simvastatin (Merck's Zocor) in the UK may "be leading to an era of less aggressive statin therapy," according to a statistical analysis presented at the Annual Scientific Sessions of the American College of Cardiology in Atlanta, Ga. March 13. OTC sale, which began in 2004, "has had an immediate and substantial impact on statin prescriptions," Kristian Filion, et al., Royal Victoria Hospital, Montreal, Canada, state. Researchers recorded statin prescriptions in the General Practice Research Database (GPRD) from the beginning of 2001 until the first quarter of 2005. Filion et al. observe that after years of increasing use, the number of statin prescriptions in the UK fell for the first time in the first quarter of 2005. "If we extrapolate from the GPRD population to the UK population of approximately 60 mil., we predict approximately 350,000 fewer statin prescriptions per quarter in the UK due to this policy change," they state. The decline in Rx statins also was not limited to 10 mg statins, but included 20 mg doses as well...

You may also be interested in...



Switch Environment Makes U.K. A Sound Warm-up For Centralized Switch

The U.K.'s bullish Rx-to-OTC switch environment can make it an attractive place to try a switch before pursuing the EU-wide centralized procedure, which contains more potential pitfalls, experts say

Angle Files De Novo Submission For Parsortix System In Breast Cancer

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

Sarepta's DMD Gene Therapy: Durable Responses After Two Years

Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel